185 related articles for article (PubMed ID: 28397089)
1. Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects.
Toshimoto K; Tomaru A; Hosokawa M; Sugiyama Y
Pharm Res; 2017 Aug; 34(8):1584-1600. PubMed ID: 28397089
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
[TBL] [Abstract][Full Text] [Related]
3. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Onoue M; Terada T; Kobayashi M; Katsura T; Matsumoto S; Yanagihara K; Nishimura T; Kanai M; Teramukai S; Shimizu A; Fukushima M; Inui K
Int J Clin Oncol; 2009 Apr; 14(2):136-42. PubMed ID: 19390945
[TBL] [Abstract][Full Text] [Related]
4. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
6. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Sai K; Saito Y; Maekawa K; Kim SR; Kaniwa N; Nishimaki-Mogami T; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Matsumura Y; Ohtsu A; Saijo N; Minami H
Cancer Chemother Pharmacol; 2010 May; 66(1):95-105. PubMed ID: 19771428
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
[No Abstract] [Full Text] [Related]
8. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
Ann Oncol; 1998 Aug; 9(8):845-7. PubMed ID: 9789606
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of irinotecan disposition and toxicity: a review.
Fujita K; Sparreboom A
Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
[TBL] [Abstract][Full Text] [Related]
10. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV
J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505
[TBL] [Abstract][Full Text] [Related]
11. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
12. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
[TBL] [Abstract][Full Text] [Related]
13. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Toffoli G; Cecchin E; Corona G; Russo A; Buonadonna A; D'Andrea M; Pasetto LM; Pessa S; Errante D; De Pangher V; Giusto M; Medici M; Gaion F; Sandri P; Galligioni E; Bonura S; Boccalon M; Biason P; Frustaci S
J Clin Oncol; 2006 Jul; 24(19):3061-8. PubMed ID: 16809730
[TBL] [Abstract][Full Text] [Related]
14. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
15. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Peng H; Duan Z; Pan D; Wen J; Wei X
Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
Deeken JF; Slack R; Marshall JL
Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
[TBL] [Abstract][Full Text] [Related]
17. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
Crona DJ; Ramirez J; Qiao W; de Graan AJ; Ratain MJ; van Schaik RH; Mathijssen RH; Rosner GL; Innocenti F
Pharmacogenomics J; 2016 Feb; 16(1):54-9. PubMed ID: 25869015
[TBL] [Abstract][Full Text] [Related]
18. [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].
Onoue M; Inui K
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1080-5. PubMed ID: 18633245
[TBL] [Abstract][Full Text] [Related]
19. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
20. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Park YH; Lee SY; Lee JS
Lung Cancer; 2009 Jan; 63(1):115-20. PubMed ID: 18221820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]